Category

News
Photo of Dr. Emile Voest
Image courtesy of The Netherlands Cancer Institute Sanofi’s Board of Directors proposes the appointment of Emile Voest and two others as independent Directors. Emile Voest is one of MOSAIC TX’s founding advisors, currently serving as director of Cancer Core Europe– a collaboration of 7 leading cancer centres in Europe, and was Executive Medical Director of...
Dr. Mathew Garnett publishes a new resource to empower precision oncology
In a recent Nature paper (23 February, 2022) Dr. Mathew Garnett, and colleagues from the Wellcome Sanger Institute unveil the world’s largest novel resource of possible new drug combinations that could represent effective therapies for some types of hard-to-treat cancers. Scientists hope that this new data will help future clinical development of combination therapies, that...
We are very excited to welcome Jose, Adam, and James to our multidisciplinary team who have joined us recently and who will be instrumental in enhancing and guiding MOSAIC’s drug discovery activities. They bring with them a diverse mix of skills and will be applying innovative data science solutions to a range of drug discovery...
Help us change the odd on cancer
Cancer is a leading cause of death reducing life expectancy in every country of the world. According to estimates from the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before the age of 70 years in 112 of 183 countries and ranks third or fourth in a further 23 countries....
Daniel Zerbino joins MOSAIC TX as Head of Data Science
Over the last few months, there has been a lot of activity at MOSAIC TX and we’re delighted to announce the arrival of our first team member Daniel Zerbino who is Head of Data Science. Daniel will have responsibility for leading the data science team within MOSAIC and is joining us from the European Bioinformatics...
Werner helicase colorectal cancer research
Work from the laboratory of Dr. Mathew Garnett recently identified Werner helicase as a synthetic-lethal target in cancers which are deficient in DNA mismatch repair.  During the AACR annual meeting, Dr. Garnett will present his recent findings, that help to refine our molecular understanding of Werner synthetic-lethality and demonstrating that Werner is a candidate target...
organoids, Garnett lab
The forward-looking review published in the journal Nature Cancer discusses key concepts in precision cancer medicine and how synthetic-lethal genetic screens can be leveraged to identify high-value oncology targets to develop better medicines for the treatment of molecularly-defined patients.
MOSAIC Therapeutics is awarded funding from Innovate UK to use whole-genome sequencing data to identify synthetic-lethal targets in colon and oesophageal cancer. The IUK award will also be used towards company formation, the setting in place of key operations, and the formation of strategic alliances with biopharma partners.  These activities will yield MOSAIC’s first targets,...
Dr. Garnett joined a panel of distinguished speakers to discuss the use of next-generation patient-derived tumour organoids to model patient responses to therapy.  His presentation showcased the use of high-fidelity cancer models that accurately reflect patient tumours, and their application for drug efficacy testing and CRISPR genetic screens. Dr. Mathew Garnett is Co-founder and Chief...
The international symposium discusses the latest innovations in drug development and target selection. Mathew presented his use of unbiased genome-scale CRISPR genetic screens to identify and prioritise oncology targets. His work led to the discovery of Werner helicase as a synthetic-lethal target in a defined set of patients with genetic alterations leading to defects in...